Yair Herishanu

24PUBLICATIONS
70CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Veterinary mycologyInnate immunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Jan 24, 2024
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL.

A Campanella, A Capasso, S Heltai

|Sep 29, 2023
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.

Andrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfò

|Apr 12, 2023
Improved outcomes in patients with chronic lymphocytic leukaemia infected during the omicron BA.5 subvariant surge.

Yotam Bronstein, Shai Levi, Yair Herishanu

|Mar 25, 2023
Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter study.

Ofrat Beyar Katz, Chava Perry, Sigal Grisariu-Greenzaid

|Feb 15, 2022
Is There a Role for [18F]FDG PET-CT in Staging MALT Lymphoma?

Dan Cohen, Chava Perry, Shir Hazut-Krauthammer

|Jan 25, 2022
BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses.

Irit Avivi, Efrat Luttwak, Esther Saiag

Pageof 4

Frequent Collaborators

5 joint publications

Francesca Romana Mauro

5 joint publications

Andrea Visentin

5 joint publications

Marzia Varettoni

5 joint publications

Tamar Tadmor